胸水脱落细胞DNA含量及VEGF表达评定对肺鳞癌胸腔积液患者预后的预测价值
|
摘要
目的评估胸水脱落细胞DNA含量及VEGF表达评定对肺鳞癌胸腔积液患者预后的预测价值。方法于2011年3月至2014年3月采用定群抽样的方法连续收集登记住我院的肺鳞癌胸腔积液患者。对患者的胸水脱落细胞DNA含量采用分光光度法进行测定;VEGF表达的定量采用免疫组化法完成。结果患者胸水脱落细胞DNA含量及VEGF表达情况及其与病程的相关性分析显示,胸水脱落细胞异倍体DNA含量及VEGF表达丰度值均与患者的生存时间呈负相关;年龄、BMI、职业、医疗保险情况、吸烟年限(年)、吸烟量(支/周)、胸水脱落细胞异倍体DNA含量以及胸水脱落细胞VEGF含量是患者中位生存时间的影响因素。结论高水平的胸水脱落细胞异倍体DNA含量以及VEGF含量是肺鳞癌胸腔积液患者预后不良的危险因素,具有一定的临床预测价值。
Objective To evaluate the predictive values of DNA content in the exfoliated cells of the pleural effusion and the assessment of VEGF expression level on the prognosis of patients with pleural effusion in squamous cell lung cancer. Methods From March 2011 to March 2014,a group sampling method was used to collect hospitalized patients with pleural effusion of lung squamous cell carcinoma. The DNA content of the exfoliated cells in the pleural effusion was measured by spectrophotometry, and the expression level of VEGF was quantified by immunohistochemistry. Results The analysis showed that the level of aneuploid DNA in exfoliated cells and the abundance of VEGF were negatively correlated the course of disease. Patients' insurance, smoking duration(years), smoking amount(branch/week), aneuploid DNA content in exfoliated pleural fluid and VEGF content in pleural fluid exfoliated cells were the influencing factors of median survival time. Conclusion High levels of aneuploid DNA in pleural fluid exfoliated cells and VEGF levels are risk factors for poor prognosis in patients with squamous cell carcinoma of the lung and have good clinical predictive values.
Objective To evaluate the predictive values of DNA content in the exfoliated cells of the pleural effusion and the assessment of VEGF expression level on the prognosis of patients with pleural effusion in squamous cell lung cancer. Methods From March 2011 to March 2014,a group sampling method was used to collect hospitalized patients with pleural effusion of lung squamous cell carcinoma. The DNA content of the exfoliated cells in the pleural effusion was measured by spectrophotometry, and the expression level of VEGF was quantified by immunohistochemistry. Results The analysis showed that the level of aneuploid DNA in exfoliated cells and the abundance of VEGF were negatively correlated the course of disease. Patients' insurance, smoking duration(years), smoking amount(branch/week), aneuploid DNA content in exfoliated pleural fluid and VEGF content in pleural fluid exfoliated cells were the influencing factors of median survival time. Conclusion High levels of aneuploid DNA in pleural fluid exfoliated cells and VEGF levels are risk factors for poor prognosis in patients with squamous cell carcinoma of the lung and have good clinical predictive values.
引文
[1]吴强,张祥海,WUQ,等.CD147和VEGF-C在肺鳞癌、腺癌中的表达与临床意义[J].中国医药科学,2016,6(6):158-161.
[2]付俊青,哈敏文,FGFR1和VEGF在肺鳞癌中的表达及其对预后影响[J].医学与哲学,2016,37(8):67-70.
[3]王磊,钟竑,梅举,等.肺鳞癌、腺癌中Survivin表达及其与VEGF和P53表达的相关性研究[J].临床肺科杂志, 2011,16(4):577-580..
[4]徐海波,熊异平,余恒勇.膀胱癌组织中MMP-2、MMP-9,Survivin、Livin和VEGF表达的临床意义分析[J].标记免疫分析与临床,2017,24(1):51-54.
[5]郭建文,左连富,刘扛惠,等.利用流式细胞术双内标进行胃癌DNA倍体分析的新方法[C].海峡两岸肿瘤学术会议.2006.
[6]梁乃超.VEGF和MMP-9检测对非小细胞肺癌患者疗效和预后评估的价值[J].检验医学与临床,2016,13(17)2529-2531.
[7] SHEPHERD F A,LACAS B,LE T G,et al. Pooled analysis of the prognostic and predictive effects of tp53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-smallcell lung cancer in four trials of adjuvant chemotherapy[J]. J Clin Oncol.2017,35(18):2018-2018.
[8]陶燕,刘泽文.VEGF及MMP表达与非小细胞肺癌的关系研究[J].实用癌症杂志,2016,31(6):889-891.
[9]年亮,胡海峰.放化疗对局部晚期非小细胞肺癌患者外周血VEGF的影响[J].实用癌症杂志,2016,31(12):1936-1939.
[10]郭守俊,曾红学,刘联斌,等.肿瘤细胞学、DNA异倍体和肿瘤标志物检测在良恶性胸腔积液鉴别诊断中的临床价值[J].实用癌症杂志,2016,31(4):681-682.
[11]张坤,段金雨,宋玉国,等.胃癌及癌前病变患者DNA倍体与T淋巴细胞检测的意义[J].世界华人消化杂志,2016, 12(9):1433-1437.
[12]逯海,陈勇,曹利英,等.细胞DNA倍体分析在食管癌临床诊断和疾病程度及预后预测中的价值[J].中国医药,2017.12(9):137-139.
[2]付俊青,哈敏文,FGFR1和VEGF在肺鳞癌中的表达及其对预后影响[J].医学与哲学,2016,37(8):67-70.
[3]王磊,钟竑,梅举,等.肺鳞癌、腺癌中Survivin表达及其与VEGF和P53表达的相关性研究[J].临床肺科杂志, 2011,16(4):577-580..
[4]徐海波,熊异平,余恒勇.膀胱癌组织中MMP-2、MMP-9,Survivin、Livin和VEGF表达的临床意义分析[J].标记免疫分析与临床,2017,24(1):51-54.
[5]郭建文,左连富,刘扛惠,等.利用流式细胞术双内标进行胃癌DNA倍体分析的新方法[C].海峡两岸肿瘤学术会议.2006.
[6]梁乃超.VEGF和MMP-9检测对非小细胞肺癌患者疗效和预后评估的价值[J].检验医学与临床,2016,13(17)2529-2531.
[7] SHEPHERD F A,LACAS B,LE T G,et al. Pooled analysis of the prognostic and predictive effects of tp53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-smallcell lung cancer in four trials of adjuvant chemotherapy[J]. J Clin Oncol.2017,35(18):2018-2018.
[8]陶燕,刘泽文.VEGF及MMP表达与非小细胞肺癌的关系研究[J].实用癌症杂志,2016,31(6):889-891.
[9]年亮,胡海峰.放化疗对局部晚期非小细胞肺癌患者外周血VEGF的影响[J].实用癌症杂志,2016,31(12):1936-1939.
[10]郭守俊,曾红学,刘联斌,等.肿瘤细胞学、DNA异倍体和肿瘤标志物检测在良恶性胸腔积液鉴别诊断中的临床价值[J].实用癌症杂志,2016,31(4):681-682.
[11]张坤,段金雨,宋玉国,等.胃癌及癌前病变患者DNA倍体与T淋巴细胞检测的意义[J].世界华人消化杂志,2016, 12(9):1433-1437.
[12]逯海,陈勇,曹利英,等.细胞DNA倍体分析在食管癌临床诊断和疾病程度及预后预测中的价值[J].中国医药,2017.12(9):137-139.